Galderma’s Post Hoc Analysis Supports Nemluvio Claims But Clearer Disclosures Needed, NAD Says

 
• By Cathy Kelly
  
Galderma 'pleased' with NAD's nuanced consideration of its post hoc analysis. (Shutterstock)

More from Marketing & Advertising

More from Compliance